Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

INTRODUCTION: The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94–9027 (damoctocog alfa pegol; Jivi(®)), a B‐domain‐deleted recombinant factor VIII (FVIII), site‐specifically PEGylated to extend its half‐life. AIM: To report the final efficacy and safety data for BAY 94–...

Descripción completa

Detalles Bibliográficos
Autores principales: Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Poulsen, Lone, Negrier, Claude, Chalasani, Pavani, Maas Enriquez, Monika, Wang, Maria, Meijer, Karina, Mancuso, Maria Elisa, Lalezari, Shadan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290859/
https://www.ncbi.nlm.nih.gov/pubmed/33818853
http://dx.doi.org/10.1111/hae.14297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290859/
https://www.ncbi.nlm.nih.gov/pubmed/33818853
http://dx.doi.org/10.1111/hae.14297

Ejemplares similares